Share

October 20, 2015; 85 (16) ArticleOpen Access

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

R. Scott Turner, Ronald G. Thomas, Suzanne Craft, Christopher H. van Dyck, Jacobo Mintzer, Brigid A. Reynolds, James B. Brewer, Robert A. Rissman, Rema Raman, Paul S. Aisen, For the Alzheimer's Disease Cooperative Study
First published September 11, 2015, DOI: https://doi.org/10.1212/WNL.0000000000002035
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
17270

Share

Article Figures & Data

Figures

  • Figure 1
    Figure 1 Flow diagram and disposition of the treatment groups

    MMSE = Mini-Mental State Examination.

  • Figure 2
    Figure 2 Effects of resveratrol on Aβ levels

    Resveratrol altered levels of CSF Aβ40 (A) and plasma Aβ40 (B) (ng/mL, mean ± SE). Similar but nonsignificant trends were found for CSF Aβ42 (C) and plasma Aβ42 (D) (ng/mL, mean ± SE). Note difference in scales. Sample sizes are indicated.

  • Figure 3
    Figure 3 Effects of resveratrol on brain volume

    Resveratrol increased brain volume loss (A, C) (mL, mean ± SE) with a corresponding increase in ventricular volume (B, D) (mL, mean ± SE). Sample sizes are indicated.

Additional Files

  • Data Supplement

    Two tables, two figures, and one appendix; three PDF files and one Microsoft Word file.

    Neurology® data supplements are not copyedited before publication. Published editorials and translations have been copyedited.
    © 2015 American Academy of Neurology.

    Files in this Data Supplement:

  • Coinvestigators

    Neurology® data supplements are not copyedited before publication. Published editorials and translations have been copyedited.
    © 2015 American Academy of Neurology.

    Files in this Data Supplement:

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me